The DOI matches its Crossref record; 138 of the 140 references it cites were found in a registry or an index.
Non-motor symptoms of Parkinson's disease: diagnosis and management
Abstract
The clinical diagnosis of Parkinson's disease rests on the identification of the characteristics related to dopamine deficiency that are a consequence of degeneration of the substantia nigra pars compacta. However, non-dopaminergic and non-motor symptoms are sometimes present before diagnosis and almost inevitably emerge with disease progression. Indeed, non-motor symptoms dominate the clinical picture of advanced Parkinson's disease and contribute to severe disability, impaired quality of life, and shortened life expectancy. By contrast with the dopaminergic symptoms of the disease, for which treatment is available, non-motor symptoms are often poorly recognised and inadequately treated. However, attention is now being focused on the recognition and quantitation of non-motor symptoms, which will form the basis of improved treatments. Some non-motor symptoms, including depression, constipation, pain, genitourinary problems, and sleep disorders, can be improved with available treatments. Other non-motor symptoms can be more refractory and need the introduction of novel non-dopaminergic drugs. Inevitably, the development of treatments that can slow or prevent the progression of Parkinson's disease and its multicentric neurodegeneration provides the best hope of curing non-motor symptoms.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Indeed, non-motor symptoms dominate the clinical picture of PD”
From Distant delivery of a mindfulness-based intervention for people with Parkinson's disease: The study protocol of a randomised pilot trial (2017) · cites this paper as [2]
In the citing paper
“and contribute to severe disability, impaired quality of life, and shortened life expectancy [2].”
From Distant delivery of a mindfulness-based intervention for people with Parkinson's disease: The study protocol of a randomised pilot trial (2017) · cites this paper as [2]
Citations
Cites
The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139
An inventory for measuring depression
BECK, A. T. (1961) · Archives of General Psychiatry · doi:10.1001/archpsyc.1961.01710120031004 · Cited by 38,032
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
A New Method for Measuring Daytime Sleepiness: The Epworth Sleepiness Scale
Johns, M. W. (1991) · Sleep · doi:10.1093/sleep/14.6.540 · Cited by 17,364
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378
Unified Parkinson's Disease Rating Scale
(2012) · Springer eBooks · doi:10.1007/springerreference_184495 · Cited by 3,071
Parkinson, J. (2002) · Journal of Neuropsychiatry · doi:10.1176/jnp.14.2.223 · Cited by 2,856
Recent developments in Parkinson's disease
Fahn, S., Elton, R., MARSDEN, C. D., Calne, D. B., & Goldstein, M. (1986) · Raven Press eBooks · Cited by 2,306
Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop
Parent, A., & Hazrati, L.-N. (1995) · Brain Research Reviews · doi:10.1016/0165-0173(94)00007-c · Cited by 2,161
Research works printed but not linked: 7
- Chaudhuri, 2004, The holistic management of Parkinson's using a novel non-motor symptom scale and questionnaire, Adv Clin Neurosci Rehab, 4, 20
- Gulati, 2004, A clinical observational study of the pattern and occurrence of non-motor symptoms in Parkinson's disease ranging from early to advanced disease, Mov Disord, 19, S406
- Abbott, 2005, Excessive daytime sleepiness and the future risk of Parkinson's disease, Mov Disord, 20, S101
- Doder, 2000, Brain serotonin 5HT1A receptors in Parkinson's disease with and without depression measured by positron emission tomography with 11C-WAY 10635, Mov Disord, 15, 213
- Diederich, 2005, Repeated visual hallucinations in Parkisnon's disease as disturbed external/internal perceptions: focused review and a new integrative model, Mov Disord, 20, 130, 10.1002/mds.20308 · DOI
- Tyvaert, 2005, Sexual dysfunction and sub-thalamic stimulation in Parkinson's disease, Park Related Disord, 11, 116
- Isaacson, 2005, Non-motor symptoms frequently herald end-of-dose wearing off in Parkinson's disease, Mov Disord, 20, S52
Cited by
Sorted by citations
Items 601–700 of 1,008
Update on the Management of Parkinson’s Disease for General Neurologists
Pirtošek, Z., Bajenaru, O. A., Kovács, N., Milanov, I. G., Relja, M., & Škorvánek, M. (2020) · Parkinson s Disease · doi:10.1155/2020/9131474 · Cited by 54
Emerging Concepts of Motor Reserve in Parkinson’s Disease
Chung, S. J., Lee, J. J., Lee, P. H., & Sohn, Y. H. (2020) · Journal of Movement Disorders · doi:10.14802/jmd.20029 · Cited by 50
Crotty, S., Fitzgerald, P., Tuohy, E., Harris, D., Fisher, A., Mandel, A., Bolton, A. E., Sullivan, A. M., & Nolan, Y. M. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.06018.x · Cited by 54
“PD clinicians have identified non-motor symptoms as a critical target for investigation if progress is to be made in development of effective treatments for PD (Chaudhuri et al., 2006).”
BackgroundInfluentialKhachnaoui, H., Mabrouk, R., & Khlifa, N. (2020) · IET Image Processing · doi:10.1049/iet-ipr.2020.1048 · Cited by 57
“Non-motor symptoms include a spectrum of benchmarks such as neurobehavioral disorders, cognitive impairment, autonomic dysfunction and so on [38, 41].”
BackgroundEffectiveness of Interventions for Dysphagia in Parkinson Disease: A Systematic Review
Gandhi, P., & Steele, C. M. (2021) · American Journal of Speech-Language Pathology · doi:10.1044/2021_ajslp-21-00145 · Cited by 56
“…(including dysphagia, hypophonia, dysarthria, and sialorrhea) are frequently noted in PD and are equally, if not more, debilitating as the hallmark features (Braak et al., 2004; Chaudhuri et al., 2006; Leopold & Kagel, 1997; Miller et al., 2006; Nilsson et al., 1996; Potulska et al., 2003).”
Treating Parkinson's disease in the 21st century: Can stem cell transplantation compete?
Buttery, P. C., & Barker, R. A. (2014) · The Journal of Comparative Neurology · doi:10.1002/cne.23577 · Cited by 53
“More important, in terms of overall disease burden, are the multiplicity of nonmotor symptoms (Chaudhuri et al., 2006).”
BackgroundEpigallocatechin-3-Gallate, a Promising Molecule for Parkinson's Disease?
Renaud, J., Nabavi, S. F., Daglia, M., Nabavi, S. M., & Martinoli, M. (2015) · Rejuvenation Research · doi:10.1089/rej.2014.1639 · Cited by 53
“83 Moreover, EGCG protects SH-SY5Y cells, a neuronal DAergic in vitro model, from oxidative stress resulting from 6-OHDA administration, 86 although Chung and colleagues have shown, on the other hand, that pre-treatment with EGCG potentiates rotenone toxicity in these same cells.”
Zhang, X.-L., Li, Y., Liu, C.-Z., Fan, R.-F., Wang, P., Zheng, L.-F., Hong, F., Feng, X.-Y., Zhang, Y., Li, L.-S., et al. (2015) · Translational Research: The Journal of Laboratory and Clinical Medicine · doi:10.1016/j.trsl.2015.02.003 · Cited by 55
Anterior cingulate integrity: Executive and neuropsychiatric features in Parkinson's disease
Lewis, S. J. G., Shine, J. M., Duffy, S. L., Halliday, G. M., & Naismith, S. L. (2012) · Movement Disorders · doi:10.1002/mds.25104 · Cited by 53
“These results suggest that loss of neuronal integrity within the ACC plays an important role in the pathophysiology underlying executive functioning and visual hallucinations in PD. VC 2012 Movement Disorder Society Key Words: Parkinson’s disease; N-acetyl aspartate; executive function; hallucinations; magnetic resona…”
BackgroundSubcutaneous apomorphine and non-motor symptoms in Parkinson's disease
Todorova, A., & Chaudhuri, К. R. (2013) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2013.08.012 · Cited by 53
Antiparkinsonian Medication and Pathological Gambling
LADER, M. H. (2008) · CNS Drugs · doi:10.2165/00023210-200822050-00004 · Cited by 52
Management of Pain in Parkinson’s Disease
Sophie, M., & Ford, B. (2012) · CNS Drugs · doi:10.1007/s40263-012-0005-2 · Cited by 53
“The estimates of frequency of pain experienced by patients with PD greatly vary between studies, ranging from 27 % [7] to 83 % [8] (see Table 1).”
BackgroundThe lifelong maintenance of mesencephalic dopaminergic neurons by Nurr1 and engrailed
Alavian, K. N., Jeddi, S., Naghipour, S. I., Nabili, P., Licznerski, P., & Tierney, T. S. (2014) · Journal of Biomedical Science · doi:10.1186/1423-0127-21-27 · Cited by 53
“Over time non-motor symptoms such as depression, constipation, pain, genitourinary problems, and sleep disorders [1,2] become prominent.”
BackgroundIntracellular soluble α‐synuclein oligomers reduce pyramidal cell excitability
Kaufmann, T. J., Harrison, P. M., Richardson, M. J. E., Pinheiro, T. J. T., & Wall, M. J. (2016) · The Journal of Physiology · doi:10.1113/jp271968 · Cited by 53
“In addition to motor dysfunction, clinically diagnosed PD patients exhibit a wide range of debilitating non-motor symptoms that have a devastating impact on quality of life (Chaudhuri et al. 2006).”
BackgroundMethodKo, W. K. D., Camus, S. M. J., Li, Q., Yang, J., McGuire, S., Pioli, E. Y., & Bézard, E. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.07.012 · Cited by 53
“…et al., 1989; Sharpe, 1990) and executive function, hat is planning and cognitive flexibility (Owen et al., 1993; Brown and Marsden, 1988; Cooper et al., 1991), are also major unmet clinical needs that significantly impact the quality of patient life (Schrag et al., 2000; Chaudhuri et al., 2006).”
BackgroundSexual dysfunction in women with Parkinson's disease
Varanda, S., da Silva, J. R., Costa, A. S., de Carvalho, C. A., Alves, J. M., Rodrigues, M., & Carneiro, G. (2016) · Movement Disorders · doi:10.1002/mds.26739 · Cited by 55
Qamar, M. A., Sauerbier, A., Politis, M., Carr, H. J., Loehrer, P. A., & Chaudhuri, К. R. (2017) · npj Parkinson s Disease · doi:10.1038/s41531-016-0006-9 · Cited by 53
“● Fatigue Fatigue is a specific NMS in PD with considerable negative impact on the quality of life of patients.(61) Some studies reported fatigue and dopaminergic dysfunction as not being significantly associated when assessed using neuroimaging.”
MethodTherapeutic singing as an early intervention for swallowing in persons with Parkinson's disease
Stegemöller, E. L., Hibbing, P. R., Radig, H., & Wingate, J. M. (2017) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2017.03.002 · Cited by 57
Freeze, B. S., Acosta, D. M., Pandya, S., Zhao, Y., & Raj, A. (2018) · NeuroImage Clinical · doi:10.1016/j.nicl.2018.01.009 · Cited by 51
“Neural circuit dysfunction in PD is pronounced throughout the brain, leading to motor deficits, as well as symptoms that include depression and visuospatial disturbances (Chaudhuri et al., 2006).”
BackgroundMadrazo, I., Kopyov, O. V., Ávila‐Rodríguez, M. A., Ostrosky, F., Carrasco, H., Kopyov, O. V., Avendaño‐Estrada, A., Jiménez, F., Magallón, E., Zamorano, C., et al. (2018) · Cell Transplantation · doi:10.1177/0963689718820271 · Cited by 53
Recent Developments in LRRK2-Targeted Therapy for Parkinson’s Disease
Zhao, Y., & Dzamko, N. L. (2019) · Drugs · doi:10.1007/s40265-019-01139-4 · Cited by 54
α-Synuclein Oligomer Detection with Aptamer Switch on Reduced Graphene Oxide Electrode
Jang, S. J., Lee, C., & Kim, T. H. (2020) · Nanomaterials · doi:10.3390/nano10050832 · Cited by 53
Autophagy-Lysosomal Pathway as Potential Therapeutic Target in Parkinson’s Disease
Bonam, S. R., Tranchant, C., & Muller, S. (2021) · Cells · doi:10.3390/cells10123547 · Cited by 54
“Furthermore, some axial symptoms (dysarthria, postural instability) are not dopa-sensitive, and clinical management of non-motor symptoms remains difficult [31,32].”
BackgroundKurihara, K., Nakagawa, R., Ishido, M., Yoshinaga, Y., Watanabe, J., Hayashi, Y., Mishima, T., Fujioka, S., & Tsuboi, Y. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.117172 · Cited by 52
“In addition, the symptomatology of PD is now recognized as heterogeneous, with clinically significant nonmotor features, such as cognitive impairment, autonomic dysfunction, neuropsychiatric symptoms, sleep disorders, pain, fatigue, and olfactory dysfunction contributing to a worsening of disability [3,4].”
Ishii, T., Furuoka, H., Kaya, M., & Kuhara, T. (2021) · Biomedicines · doi:10.3390/biomedicines9020167 · Cited by 50
“Non-motor symptoms sometimes appear in patients with PD before the onset of motor dysfunction [2,3].”
BackgroundLang, A. E., Eberly, S. W., Goetz, C. G., Stebbins, G. T., Oakes, D., MAREK, K. L., Ravina, B. M., Tanner, C. M., Shoulson, I., & on behalf of the LABS‐PD investigators (2013) · Movement Disorders · doi:10.1002/mds.25671 · Cited by 52
Behavioral analysis of motor and non-motor symptoms in rodent models of Parkinson’s disease
Dunnett, S. B., & Lelos, M. J. (2010) · Progress in brain research · doi:10.1016/s0079-6123(10)84003-8 · Cited by 52
Influence of depression in mild Parkinson's disease on longitudinal motor and cognitive function
Ng, A. Y. T., Chander, R. J., Tan, L. C. S., & Kandiah, N. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.06.014 · Cited by 52
Attenuated heart rate response in REM sleep behavior disorder and Parkinson's disease
Sørensen, G. L., Kempfner, J., Zoetmulder, M., Sørensen, H. B. D., & Jennum, P. (2012) · Movement Disorders · doi:10.1002/mds.25012 · Cited by 54
“The degeneration and dysfunction include nuclei-mediating autonomic functions such as the dorsal vagal nucleus, nucleus ambiguus, and other medullary centers, which exert differential control on the sympathetic preganglionic neurons via descending pathways.(2) Parasympathetic and sympathetic functions may be impaired.”
BackgroundDisease-modifying drugs and Parkinson's disease
Allain, H., Bentué‐Ferrer, D., & Akwa, Y. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.10.003 · Cited by 52
Ghrelin as a Neuroprotective and Palliative Agent in Alzheimer's and Parkinson's Disease
dos Santos, V. V., Rodrigues, A. L. S., de Lima, T. C. M., de Barioglio, S. R., Raisman‐Vozari, R., & Prediger, R. D. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113199990411 · Cited by 53
Cognition, coping, and outcome in Parkinson's disease
Hurt, C. S., Landau, S., Burn, D. J., Hindle, J. V., Samuel, M., Wilson, K., & Brown, R. G. (2012) · International Psychogeriatrics · doi:10.1017/s1041610212000749 · Cited by 52
“In addition, PD is associated with a range of nonmotor symptoms including cognitive impairment, depression, and anxiety (Chaudhuri et al., 2006).”
BackgroundSantos‐García, D., Castro, E. S., Expósito, I., de Deus, T., Gesto, C. T., Aneiros, Á., Fernández, M., Núñez-Arias, D., & Torres, M. B. (2016) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2016.12.046 · Cited by 52
Scorza, F. A., do Carmo, A. C., FIORINI, A. C., Nejm, M. B., Scorza, C. A., Finsterer, J., & Ferraz, H. B. (2017) · Clinics · doi:10.6061/clinics/2017(11)01 · Cited by 52
Association between antidepressants and falls in Parkinson’s disease
Martínez-Ramírez, D., Giugni, J. C., Almeida, L., Walz, R., Ahmed, B., Chai, F. A., Rundle-Gonzalez, V., Bona, A. R., Hastings, E., Shukla, A. W., et al. (2015) · Journal of Neurology · doi:10.1007/s00415-015-7947-5 · Cited by 51
Magistrelli, L., Contaldi, E., & Comi, C. (2021) · Life · doi:10.3390/life11080804 · Cited by 63
“It is therefore important for clinicians to recognize and monitor these symptoms using the already validated clinical scales [11].”
BackgroundPark, J. S., Choe, K., Lee, H. J., Park, T. J., & Kim, M. O. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-023-00961-z · Cited by 51
“Additionally, PD has nonmotor symptoms, including cognitive impairment [11].”
BackgroundMakaroff, L., Gunn, A., Gervasoni, C., & Richy, F. F. (2011) · Journal of Parkinson s Disease · doi:10.3233/jpd-2011-001 · Cited by 51
Medical Treatment of Parkinson Disease
Stacy, M. A. (2009) · Neurologic Clinics · doi:10.1016/j.ncl.2009.04.009 · Cited by 54
Reimann, M., Schmidt, C., Herting, B., Prieur, S., Junghanns, S., Schweitzer, K. J., Globas, C., Schöls, L. J., Reichmann, H., Berg, D., et al. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0313-y · Cited by 51
“However, non-motor symptoms such as autonomic, sensory, psychic and cognitive dysfunctions figure prominently in a variety of extrapyramidal disorders ( Chaudhuri et al. 2006; Friedrich et al. 2008; Poewe 2008; Schmidt et al. 2008a, b). Despite being socially disabling, these symptoms have as yet received rather littl…”
Martínez‐Martín, P., TOLOSA, E. S., Hernandez, B., Badia, X. C., & ValidQUICK Study Group (2008) · Movement Disorders · doi:10.1002/mds.21944 · Cited by 51
“To determine (1) in the setting of routine clinical practice, the quality attributes (sensitivity and specificity) of the QQ as a tool for diagnosis of WO in Spanish population with PD; (2) the relationship between the results of QQ application and factors concerning the clinical condition and course of the disease; a…”
MethodHow integrated are neurology and palliative care services? Results of a multicentre mapping exercise
Neuro, O. B. O. O., van Vliet, L. M., Gao, W., DiFrancesco, D., Crosby, V., Wilcock, A., Byrne, A., Al‐Chalabi, A., Chaudhuri, К. R., Evans, C., et al. (2016) · BMC Neurology · doi:10.1186/s12883-016-0583-6 · Cited by 51
“Background Patients severely affected by progressive long-term neurological conditions such as Multiple Sclerosis (MS), Parkinson’s Disease (PD), Multiple-System Atrophy (MSA), Progressive Supranuclear Palsy (PSP) (grouped together as Parkinsonism), and Motor Neuron Disease (MND) have unmet physical and psychological…”
BackgroundCognitive Training in Parkinson’s Disease
Walton, C. C., Naismith, S. L., Lampit, A., Mowszowski, L., & Lewis, S. J. G. (2016) · Neurorehabilitation and neural repair · doi:10.1177/1545968316680489 · Cited by 51
Associations between cognitive impairment and motor dysfunction in Parkinson's disease
Wang, Y., Zhao, J., Li, D., Peng, F., Wang, Y., Yang, K., Liu, Z., Liu, F., Wu, J., & Wang, J. (2017) · Brain and Behavior · doi:10.1002/brb3.719 · Cited by 52
Choudhury, G. R., & Daadi, M. M. (2018) · PLoS ONE · doi:10.1371/journal.pone.0202770 · Cited by 51
Dujardin, K., & Sgambato, V. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00025 · Cited by 46
Mining genetic and transcriptomic data using machine learning approaches in Parkinson’s disease
Su, C., Tong, J., & Wang, F. (2020) · npj Parkinson s Disease · doi:10.1038/s41531-020-00127-w · Cited by 56
Oudsten, B. L. D., Lucas, R., Green, A. M., & The Whoqol-Dis Group (2011) · Disability and Rehabilitation · doi:10.3109/09638288.2011.575527 · Cited by 53
Psychological Predictors of Anxiety and Depression in Parkinson's Disease: A Systematic Review
Garlovsky, J. K., Overton, P. G., & Simpson, J. (2016) · Journal of Clinical Psychology · doi:10.1002/jclp.22308 · Cited by 49
“Anxiety and depression in PD have typically been considered as non-motor symptoms resulting from the neurochemical changes found in the brains of people with PD (Chaudhuri et al., 2006; Chaudhuri & Schapira, 2009; Leentjens, Dujardin, Martinez-Martin, Richard, & Starkstein, 2011).”
BackgroundMadiha, S., Batool, Z., Tabassum, S., Liaquat, L., Sadir, S., Shahzad, S., Naqvi, F. F., Saleem, S., Yousuf, S., Nawaz, A., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0258928 · Cited by 52
“Like motor symptoms, non-motor symptoms in PD also have significance due to their presence before the disease diagnosis or appearance with the disease progression [72].”
BackgroundPharmacology of Metabotropic Glutamate Receptor Allosteric Modulators
Gregory, K. J., Noetzel, M. J., & Niswender, C. M. (2013) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-394587-7.00002-6 · Cited by 54
Alcock, L., Galna, B., Lord, S., & Rochester, L. (2016) · Journal of Biomechanics · doi:10.1016/j.jbiomech.2016.06.007 · Cited by 50
Lim, J., Bang, Y., Choi, J.-H., Han, A., Kwon, M., Liu, K., & Choi, H. J. (2018) · Journal of Neuroscience · doi:10.1523/jneurosci.4051-15.2017 · Cited by 50
“In most cases, the nonmotor symptoms precede the classical motor features by years (Chaudhuri et al., 2006).”
BackgroundHistone Deacetylase Inhibitors: A Therapeutic Key in Neurological Disorders?
Ziemka‐Nałęcz, M., Jaworska, J., Sypecka, J., & Zalewska, T. (2018) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nly073 · Cited by 53
Qureshi, A. R., Rana, A. Q., Malik, S. H., Rizvi, S. F. H., Akhter, S., Vannabouathong, C., Sarfraz, Z., & Rana, R. (2018) · Neuroepidemiology · doi:10.1159/000492221 · Cited by 50
Symptom burden among individuals with Parkinson disease
Tarolli, C. G., Zimmerman, G. A., Auinger, P., McIntosh, S. E., Horowitz, R. K., Kluger, B. M., Dorsey, E. R., & Holloway, R. G. (2020) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000000746 · Cited by 52
Subrahmanian, N., & LaVoie, M. J. (2021) · Brain Research · doi:10.1016/j.brainres.2021.147434 · Cited by 48
Current concepts in the management of Parkinson disease
Hayes, M. W., Fung, V. S. C., Kimber, T. E., & O’Sullivan, J. D. (2010) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2010.tb03453.x · Cited by 51
Sleep Disturbances in Parkinson Disease and Their Potential Role in Heterogeneity
Gunn, D. G., Naismith, S. L., & Lewis, S. J. G. (2010) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988709358591 · Cited by 49
“Insomnia represents persistent difficulty in initiating or maintaining sleep, the causes of which in PD are varied and may relate to physical discomfort, nocturia, or restless leg movements.(2) Sleep maintenance insomnia appears to be more common in PD than initial insomnia,(4) but the neurobiology underlying these di…”
BackgroundLiu, W., Tung, T., Zhang, C., & Shi, L. (2022) · Brain and Behavior · doi:10.1002/brb3.2690 · Cited by 55
“…Contreras & Grandas, 2012; Matinolli et al., 2007; Robinson et al., 2005; Wood et al., 2002), cognitive impairment (Camicioli & Majumdar, 2010; Chaudhuri et al., 2006; Ffytche et al., 2017; Latt et al., 2009; Paul et al., 2014), overconfidence (Davidsdottir et al., 2008; Gullett et al., 2013;…”
BackgroundBeta amyloid deposition and cognitive decline in Parkinson’s disease: a study of the PPMI cohort
Mihaescu, A. S., Valli, M., Uribe, C., Díez‐Cirarda, M., Masellis, M., Graff‐Guerrero, A., & Strafella, A. P. (2022) · Molecular Brain · doi:10.1186/s13041-022-00964-1 · Cited by 53
“Introduction Parkinson’s disease (PD) is the second most common neurodegenerative disorder, presenting with progressively deteriorating motor and cognitive symptoms [1, 2].”
BackgroundHow well do we recognise non-motor symptoms in a British Parkinson’s disease population?
Hu, M., Cooper, J., Beamish, R., Jones, E., Butterworth, R. J., Catterall, L., & Ben‐Shlomo, Y. (2011) · Journal of Neurology · doi:10.1007/s00415-011-5972-6 · Cited by 49
“Non-motor symptoms amongst patients with Parkinson’s disease (PD) have gained increasing awareness amongst movement disorder specialists over the past decade [6, 9] and have a major effect on quality-of-life, health resource use and rates of institutionalisation among PD patients [2, 11, 21, 24, 29].”
BackgroundCôté, M., Poirier, A.-A., Aubé, B., Jobin, C., Lacroix, S., & Soulet, D. (2015) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2015.01.009 · Cited by 54
Non-motor symptoms of Parkinson’s disease in China: A review of the literature
Chen, W., Xu, Z., Wang, G., & Chen, S. (2012) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2012.02.002 · Cited by 49
Morais, L. H., Lima, M. M. S., Martynhak, B. J., Santiago, R. M., Takahashi, T. T., Ariza, D., Barbiero, J. K., Andreatini, R., & Vital, M. A. B. F. (2012) · Pharmacological Reports · doi:10.1016/s1734-1140(12)70905-2 · Cited by 49
Idiopathic Parkinson's disease patients at the urologic clinic
Ragab, M. M., & Mohammed, E. S. (2011) · Neurourology and Urodynamics · doi:10.1002/nau.20983 · Cited by 49
Neuropsychiatry of Parkinson's disease
Kümmer, A., & Teixeira, A. L. (2009) · Arquivos de Neuro-Psiquiatria · doi:10.1590/s0004-282x2009000500033 · Cited by 49
Induced pluripotent stem cells in the study of neurological diseases
Saporta, M., Grs̆ković, M., & Dimos, J. T. (2011) · Stem Cell Research & Therapy · doi:10.1186/scrt78 · Cited by 50
“A group of nonmotor PD-related symptoms has been increasingly recognized [36], suggesting that other neuronal cell types may also be aff ected.”
BackgroundKasai, S., Yoshihara, T., Lopatina, O. L., Ishihara, K., & Higashida, H. (2017) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2017.00075 · Cited by 50
“The classic treatment L-3,4-dihydroxyphenylalanine (levodopa) has little effect on most non-motor symptoms (Chaudhuri et al., 2006), and chronic administration is associated with a risk of depression and anxiety (Damãsio et al., 1971; Marsh and Markham, 1973; Choi et al., 2000; Nègre-Pagès et al.,…”
BackgroundSexual Dysfunctions in Parkinson's Disease: An Underrated Problem in a Much Discussed Disorder
Bhattacharyya, K., & Rosa‐Grilo, M. (2017) · International review of neurobiology · doi:10.1016/bs.irn.2017.05.019 · Cited by 49
Validation of the Italian version of the Non Motor Symptoms Scale for Parkinson's disease
Cova, I., Battista, M. E. D., Vanacore, N., Papi, C. P., Alampi, G., Rubino, A., Valente, M., Meco, G., Contri, P., Pucchio, A. D., et al. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2016.10.020 · Cited by 49
Differences in odor identification among clinical subtypes of Parkinson’s disease
Iijima, M., Kobayakawa, T., Saito, S., Osawa, M., Tsutsumi, Y., Hashimoto, S., & Uchiyama, S. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03167.x · Cited by 49
“The smell identification ability in Japanese patients with idiopathic PD is impaired based on the odor stick identification test for Japanese (OSIT-J) [2,3] as well as previous reports [1,4,5].”
BackgroundMethodTreating Parkinson’s disease by astrocyte reprogramming: Progress and challenges
Wei, Z. D., & Shetty, A. K. (2021) · Science Advances · doi:10.1126/sciadv.abg3198 · Cited by 50
“The Braak stages suggest that the nonmotor symptoms occur in the preclinical stages 1 and 2 when the disease is mostly restricted to the olfactory bulb and lower brainstem (11).”
BackgroundFunctional Brain Dysconnectivity in Parkinson's Disease: A 5‐Year Longitudinal Study
Yassine, S., Gschwandtner, U., Auffret, M., Achard, S., Vérin, M., Fuhr, P., & Hassan, M. (2022) · Movement Disorders · doi:10.1002/mds.29026 · Cited by 49
“2-4 Pathologically, the most prevalent hypotheses suggest that the degeneration of dopaminergic neurons in the nigrostriatal system associated with Lewy body inclusions are the leading features in most forms of PD at early stages.”
Side of Onset in Parkinson’s Disease and Alterations in Religiosity: Novel Behavioral Phenotypes
Butler, P. M., McNamara, P., & Durso, R. (2011) · Behavioural Neurology · doi:10.1155/2011/493013 · Cited by 48
Li, S., Ritz, B. R., Gong, Y., Cockburn, M., Folle, A. D., Rosario, I. D., Yu, Y., Zhang, K., Castro, E., Keener, A. M., et al. (2022) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2022.160851 · Cited by 48
“We also recognize that there are other PD-related motor and non-motor symptoms that were not investigated in our study, including dysautonomia, pain, and sleep disorders (Chaudhuri et al., 2006).”
BackgroundParkinson’s disease diagnosis using deep learning: A bibliometric analysis and literature review
Abumalloh, R. A., Nilashi, M., Samad, S., Ahmadi, H., Alghamdi, A., Alrizq, M., & AlYami, S. S. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102285 · Cited by 51
Varanese, S., Perfetti, B., Monaco, D., Thomas, A., Bonanni, L., Tiraboschi, P., & ONOFRJ, M. C. (2010) · Journal of Neurology · doi:10.1007/s00415-010-5453-3 · Cited by 48
“In recent years it has become apparent that non-motor symptoms of PD, including dementia and behavioural disorders, form an important part of this condition [7].”
BackgroundDepression in Parkinson's disease: diagnosis and treatment
Costa, F. H. D. R., de Rosso, A. L. Z., Maultasch, H., Nicaretta, D. H., & Vincent, M. B. (2012) · Arquivos de Neuro-Psiquiatria · doi:10.1590/s0004-282x2012000800011 · Cited by 48
Parkinson's disease: 10 years of progress, 1997–2007
Fahn, S. (2010) · Movement Disorders · doi:10.1002/mds.22796 · Cited by 51
When does Parkinson's disease begin? From prodromal disease to motor signs
Meissner, W. G. (2012) · Revue Neurologique · doi:10.1016/j.neurol.2012.07.004 · Cited by 51
Kitta, T., Chancellor, M. B., de Groat, W. C., Kuno, S., Nonomura, K., & Yoshimura, N. (2012) · The Journal of Urology · doi:10.1016/j.juro.2011.12.062 · Cited by 48
Markerless Analysis of Articulatory Movements in Patients With Parkinson's Disease
Bandini, A., Orlandi, S., Giovannelli, F., Felici, A., Cincotta, M., Clemente, D., Vanni, P., Zaccara, G., & Manfredi, C. (2015) · Journal of Voice · doi:10.1016/j.jvoice.2015.10.014 · Cited by 54
“Cardinal motor symptoms of PD are rest tremor, bradykinesia, and rigidity.(4,5) Other common motor signs involve the control of speech production, affecting motion and coordination of the articulatory organs (ie, tongue, lips, and jaw).”
BackgroundZeng, L., Xie, L., Shen, H., Luo, Z., Fang, P., Hou, Y., Tang, B., Wu, T., & Hu, D. (2016) · The Cerebellum · doi:10.1007/s12311-016-0781-1 · Cited by 48
“Cognitive and executive deficits are very common in PD; the gray matter alterations in the left medial and right cerebellar Crus I may be related to such deficits that are optionally present in PD [1, 16].”
BackgroundNeural mechanisms underlying cognitive inflexibility in Parkinson's disease
Lange, F., Seer, C., Loens, S., Wegner, F., Schrader, C., Dressler, D. W., Dengler, R., & Kopp, B. (2016) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2016.09.021 · Cited by 48
Impact of autonomic dysfunctions on the quality of life in Parkinson’s disease patients
Tomić, S., Rajkovaca, I., Pekić, V., Salha, T., & Mišević, S. (2016) · Acta Neurologica Belgica · doi:10.1007/s13760-016-0739-6 · Cited by 48
Advances in the development of imaging probes and aggregation inhibitors for alpha-synuclein
Xu, M., Ryan, P., Rudrawar, S., Quinn, R. J., Zhang, H., & Mellick, G. D. (2019) · Acta Pharmacologica Sinica · doi:10.1038/s41401-019-0304-y · Cited by 49
“With disease progression, nonmotor symptoms, such as depression, psychosis, falls, and sleep disturbance, also emerge [2].”
BackgroundAdvances in the Research of Risk Factors and Prodromal Biomarkers of Parkinson’s Disease
Xie, F., Gao, X., Yang, W., Chang, Z., Yang, X., Wei, X., Huang, Z., Xie, H., Yue, Z., Zhou, F., et al. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00520 · Cited by 47
The initial diagnosis and management of Parkinson’s disease
Waller, S. E., Williams, L., Morales‐Briceño, H., & Fung, V. S. C. (2021) · Australian Journal of General Practice · doi:10.31128/ajgp-07-21-6087 · Cited by 47
Gerrits, N. J. H. M., van der Werf, Y. D., Verhoef, K. M. W., Veltman, D. J., Groenewegen, H. J., Berendse, H. W., & van den Heuvel, O. A. (2015) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2014.12.022 · Cited by 47
Safinamide in the treatment of Parkinson's disease
Schapira, A. H. V. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.511612 · Cited by 47
“Parkinson’s disease (PD) is a common neurodegenerative disease that manifests with a range of motor and non-motor clinical features [1,2].”
BackgroundSelf-citationNonmotor presentations of multiple system atrophy
Colosimo, C. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.5 · Cited by 47
Parkinson's Disease: Barriers and Facilitators to Optimizing Function
Pretzer‐Aboff, I., Galik, E. M., & Resnick, B. M. (2009) · Rehabilitation Nursing · doi:10.1002/j.2048-7940.2009.tb00249.x · Cited by 47
Calcium dysregulation in Parkinson’s disease
Schapira, A. H. V. (2013) · Brain · doi:10.1093/brain/awt180 · Cited by 47
“Non-dopaminergic neuronal loss in Parkinson’s disease is associated with a considerable clinical burden that increases with disease progression and becomes the predominant determinant of quality of life, and the requirements and costs for long-term care in these patients (Chaudhuri et al., 2006).”
Self-citationProton MR Spectroscopy for Diagnosis and Evaluation of Treatment Efficacy in Parkinson Disease
Mazuel, L., Chassain, C., Jean, B., Pereira, B., Cladière, A., Spéziale, C., & Durif, F. (2015) · Radiology · doi:10.1148/radiol.2015142764 · Cited by 47
Smith, N. J. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00275 · Cited by 47
“…interaction between GPR37 expression and affective disorders is also relevant to PD, as PD patients often experience non-motor symptoms involvingmood, sleep, memory and learning and sensorimotor disturbances, as well as olfactory and gastrointestinal perturbations (Chaudhuri et al., 2006).”
BackgroundAssociation of Restless Legs Syndrome With Incident Parkinson’s Disease
Szatmári, S., Bereczki, D., Fornadi, K., Kalantar‐Zadeh, K., Kovesdy, C. P., & Molnar, M. Z. (2016) · SLEEP · doi:10.1093/sleep/zsw065 · Cited by 49
Does REM sleep behavior disorder change in the progression of Parkinson’s disease?
Figorilli, M., Marquès, A., Vidal, T., Delaby, L., Meloni, M., Pereira, B., Lambert, C., Puligheddu, M., Durif, F., & Fantini, M. L. (2020) · Sleep Medicine · doi:10.1016/j.sleep.2019.12.013 · Cited by 47
Córneo, E. D. S., Silveira, G. D. B., Scussel, R., Corrêa, M. E. A. B., Abel, J. D. S., Luiz, G. P., Feuser, P. E., Silveira, P. C. L., & Machado‐de‐Ávila, R. A. (2020) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2020.111302 · Cited by 47
Frandsen, R. A. V., Baandrup, L., Kjellberg, J., Ibsen, R., & Jennum, P. (2014) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2014.07.012 · Cited by 46
“However, other regions of the brain are affected that are associated with non-motor symptoms [8], such as mood changes, depression [9], hallucinations, and sleep complaints including a type of increased motor”
Background
Metadata
- Authors
- Chaudhuri, K. R., Healy, D. G., & Schapira, A. H.
- Affiliations
- Guy's and St Thomas' NHS Foundation Trust (GB)
- The Royal Free Hospital (GB)
- ORCID
- Schapira, Anthony HV
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2006-03
- Volume
- 5
- Issue
- 3
- Pages
- 235-245
- ISSN
- 1474-4422 (ISSN-L)
- OpenAlex
- W1982535961
- Cited by
- 2,807
- References
- 140
- Citations by year
- 2026: 184 · 2025: 170 · 2024: 143 · 2023: 159 · 2022: 168 · 2021: 165 · 2020: 197 · 2019: 168 · 2018: 161 · 2017: 174 · 2016: 152 · 2015: 156 · 2014: 130 · 2013: 130 · 2012: 129
- FWCI
- 9.23
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet Neurology (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Parkinson's disease, non-motor symptoms, depression, constipation, pain, genitourinary dysfunction, sleep disorders, substantia nigra pars compacta, neurodegeneration, quality of life, disability
- MeSH terms
- Autonomic Nervous System Diseases, Humans, Pain, Parkinson Disease, Psychotic Disorders, Sleep Wake Disorders, Disease Progression, Pain Management
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
